Universal API Implementation Guide - Local Development build (v1.1.20) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

Release 2026 May 15

ANNOUNCEMENTS

• Copay Questionnaire: Indication for VENCLEXTA and acalabrutinib for CLL/SLL is available in production and all test environments as of 5/15/2026.
  
  

Copay Questionnaire Updates

Type	Release to Production	Available in QA (test) environment?	Product(s) impacted	linkId impacted (if applicable)	OLD	New	Comment
Add	5/15/2026	Yes	Venclexta	linkId: venclexta-fda-approved-indications	-	valueCoding.code: acalabrutinib-combination valueCoding.display: VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) -VENCLEXTA monotherapy is used for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) -VENCLEXTA and acalabrutinib are used for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)	New CLL/SLL Indication